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ABSTRACT
Objectives: To determine whether low-dose
spironolactone can safely lower arterial stiffness in
patients with chronic kidney disease stage 3 in the
primary care setting.
Design: A multicentre, prospective, randomised,
placebo-controlled, double-blinded study.
Setting: 11 primary care centres in South
Birmingham, England.
Participants: Adult patients with stage 3 chronic
kidney disease. Main exclusion criteria were diagnosis
of diabetes mellitus, chronic heart failure, atrial
fibrillation, severe hypertension, systolic blood pressure
<120 mm Hg or baseline serum potassium ≥5 mmol/L.
Intervention: Eligible participants were randomised to
receive either spironolactone 25 mg once daily, or
matching placebo for an intended period of 40 weeks.
Outcome measures: The primary end point was the
change in arterial stiffness as measured by pulse wave
velocity. Secondary outcome measures included the
rate of hyperkalaemia, deterioration of renal function,
barriers to participation and expected recruitment rates
to a potential future hard end point study.
Results: From the 11 practices serving a population of
112 462, there were 1598 (1.4%) patients identified as
being eligible and were invited to participate. Of these, 134
(8.4%) attended the screening visit of which only 16
(1.0%) were eligible for randomisation. The main reasons
for exclusion were low systolic blood pressure
(<120 mm Hg: 40 patients) and high estimated glomerular
filtration rate (≥60 mL/min/1.73 m2: 38 patients). The trial
was considered unfeasible and was terminated early.
Conclusions:We highlight some of the challenges in
undertaking research in primary care including patient
participation in trials. This study not only challenged our
preconceptions, but also provided important learning for
future research in this large and important group of
patients.
Trial registration number: ISRCTN80658312.
INTRODUCTION
Chronic kidney disease (CKD) is increasingly
recognised as an independent risk factor for
cardiovascular (CV) morbidity and mortality.1–4
Although the increased CV risk observed in
dialysis patients is considerable, the global
health burden of CV disease in the earlier
stages of CKD is likely to be much greater
given the high reported prevalence of up to
13% in developed countries.5 6 In addition to
an increased risk of vasculo-occlusive events
such as myocardial infarction, patients with
CKD also have an increased risk of cardiac
arrhythmias and heart failure.7 8 Increased
arterial stiffness, leading to myocardial hyper-
trophy and ﬁbrosis is thought to be a key
mechanistic pathway in this pathophysiology of
this increased CV risk.7 9–11 Many of these
abnormalities are indeed already evident in
patients with only mild abnormalities of kidney
function (estimated glomerular ﬁltration rates
(eGFRs): 30–90 mL/min/1.73 m2).12–14
Activation of the renin-angiotensin-
aldosterone system (RAAS) is a key mediator
of the arterial and cardiac changes observed
in patients with CKD, as well as the increased
Strengths and limitations of this study
▪ This is the first reported randomised, placebo-
controlled interventional trial of patients with
stage 3 chronic kidney disease in the primary
care setting in England.
▪ The strengths of the study are the original study
design, setting and populations.
▪ The review of the list of potential participants by
their corresponding general practitioners might
have resulted in selection bias.
▪ The major limitation to this study was the poor
recruitment which ultimately led to early termin-
ation of the study.
▪ Critical analysis and transparent reporting of
research recruitment failure provide important
learning for future research in this large and
important group of patients.
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CV risk associated with this condition.15 16 Aldosterone
is a mineralocorticoid, that is, a key effector of the
RAAS. The mineralocorticoid receptor antagonist
(MRA), spironolactone, used in low dose, has been
shown to signiﬁcantly lower arterial stiffness and left ven-
tricular mass in patients with stage 3 CKD managed by
nephrologists in secondary care.17 However, the majority
(>90%) of patients with this level of kidney function are
managed in primary care by their general practitioners
(GP).18 19 These patients tend to be older and have non-
proteinuric renal diseases probably as a consequence of
hypertension, renovascular disease and, possibly, normal
ageing.20 21 Furthermore, concerns about MRAs causing
hyperkalaemia and worsening renal function might limit
their future use in the primary care setting.
We, therefore, undertook a feasibility study to examine
the actions of low-dose spironolactone on arterial stiff-
ness in non-diabetic patients with stage 3 CKD managed
in primary care. Secondary objectives included the rate
of hyperkalaemia, deterioration of renal function, bar-
riers to participation and expected recruitment rates to
a potential future hard end point study.
SUBJECTS AND METHODS
The study design has previously been described in detail
(see online supplementary appendix 1).22 In brief, it
was a multicentre, prospective, randomised, placebo-
controlled, double-blind, parallel trial in non-diabetic
patients with conﬁrmed stage 3 CKD over 18 years of
age in primary care. Patients with diabetes mellitus were
excluded given that the pathophysiology of arterial stiff-
ness is likely to be different, and they have a higher risk
of hyperkalaemia.23 Diabetes would be expected to
affect 20–30% of a community sample of CKD, and
hence, would form a large subgroup within the trial.
Thus, although diabetes is an important issue in CKD,
we considered that this would be best explored in a sep-
arate study.
The GFR was estimated by the four-variable
Modiﬁcation of Diet in Renal Disease (MDRD) formula
with serum creatinine recalibrated to be traceable to an
isotope-derived mass spectroscopy method.24 The full
inclusion and exclusion criteria are detailed in box 1.
The UK National Institute for Health and Care
Excellence (NICE) guidelines on CKD recommended
systolic blood pressure (BP) (SBP) target range of 120–
139 mm Hg, and diastolic BP (DBP) <90 mm Hg for
patients with CKD.25 As spironolactone is known to have
a BP-lowering effect, patients with SBP <120 mm Hg or
postural hypotension were excluded from the study.26 In
addition, due to the increased risk of hyperkalaemia
associated with the use of spironolactone, patients with a
serum potassium ≥5 mmol/L, or those already receiving
both angiotensin converting enzyme inhibitor (ACEi)
and angiotensin II receptor blocker (ARB) were also
excluded from the study.27 Patients with uncontrolled
severe hypertension (BP ≥180/110 mm Hg) were
deemed inappropriate for the study as they required
urgent antihypertensive treatment,26 and so were
patients with urine albumin:creatinine ratio (uACR)
≥70 mg/mmol who should be referred and managed in
a secondary care setting.
Practices’ electronic patient records (EPR) were
screened to identify all patients whose latest eGFRs were
30–59 mL/min/1.73 m2 in the preceding 12 months,
and satisﬁed the study inclusion and exclusion criteria.
Following review by individual patient’s GPs to deter-
mine suitability for participation, potential participants
were sent postal invitations addressed from their GPs
(see online supplementary appendix 2). Non-responders
were sent a second invitation 2 weeks later. Those
expressing a willingness to participate were invited to
attend a screening visit at their own general practice to
conﬁrm eligibility. Following this screening visit, eligible
participants attended a randomisation visit within
2 weeks, and if still eligible were assigned 1:1 to receive
either spironolactone 25 mg once daily orally, or an
identical placebo for 40 weeks using a web-based
Box 1 Inclusion and exclusion criteria of Spironolactone
To Prevent Cardiovascular Events in Early Stage chronic
kidney disease (STOP-CKD) study
Inclusion criteria
▸ Age over 18 years
▸ Diagnosis of CKD stage 3 (modification of diet in renal disease
(MDRD) estimated glomerular filtration rate (eGFR) 30–59 mL/
min/1.73 m2, sustained for at least 90 days)
Exclusion criteria
▸ Diabetes mellitus
▸ Terminal disease or considered otherwise unsuitable by
general practitioner
▸ Clinical diagnosis of chronic heart failure
▸ Atrial fibrillation
▸ Alcohol or drug abuse
▸ Inability to comply with trial medication and follow-up
▸ Documented previous hyperkalaemia or intolerance of
spironolactone
▸ Documented Addisonian crisis or taking fludrocortisone
▸ Severe hypertension: blood pressure (BP) ≥180/110 mm Hg
▸ Systolic BP<120 mm Hg
▸ Recent acute kidney injury or hospital admission (within previ-
ous 6 weeks)
▸ Chronic diarrhoea
▸ Urine albumin:creatinine ratio (uACR)≥70 mg/mmol
▸ Serum potassium≥5 mmol/L on screening visit
▸ Concomitant co-trimoxazole medication
▸ Concomitant angiotensin converting enzyme inhibitor (ACEi)
and angiotensin II receptor blocker (ARB) medication (dual-
angiotensin blockade)
▸ Concomitant lithium medication
▸ Concomitant warfarin medication
▸ Pregnancy
▸ Breast feeding
▸ Planned major surgical intervention within 46 weeks of
recruitment
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randomisation system (see online supplementary appen-
dix 1). Investigator, outcome assessors, data analysts and
participants were all blinded to the treatment allocation.
Patients were given a prescription to collect their study
medication from their local community pharmacy.
Arterial stiffness, as determined by carotid-femoral pulse
wave velocity (cfPWV) was measured using the Vicorder
system (Skidmore, Bristol, UK)28 at randomisation visit
and 40 weeks. Blood pressure was measured using the
BpTRU BPM-100 automated BP monitor, which was set
to obtain six serial BP readings, at 1 min intervals.29 The
mean ofﬁce BP was derived from the 2nd and 3rd BP
readings, whereas the mean BpTRU reading was derived
from the 2nd to 6th readings.30 Postural hypotension
was deﬁned as a drop of SBP >20 mm Hg after a minute
on standing.
The Primary Care Clinical Research and Trials Unit
(PC-CRTU) at the University of Birmingham coordi-
nated the study (trial registration number
ISRCTN80658312).
Sample size calculation
In a previous study of the effect of spironolactone, the
SD of the change in cfPWV was 1.0 m/s in the active
treatment group and 0.9 m/s in the control group.31
Hence, 100 participants in each arm would provide 90%
power with an α value of 0.05 to detect a difference in
change of cfPWV of 0.5 m/s between the active treat-
ment and control groups. The study, therefore, intended
to recruit 240 patients to account for an approximate
dropout rate of 20%, which would result in at least 200
evaluable patients completing this trial.
Statistical analysis
Statistical analyses were performed using SPSS V.20
(SPSS Inc, Chicago, Illinois, USA), and SAS V.9.4 (SAS
Institute; Cary, North Carolina, USA). Numerical values
are expressed as mean (SD) for parametric data, or
median (IQR) for non-parametric data. Normality of the
distribution of data was assessed by visual inspection of
histogram and normal probability plot. Non-parametric
data were loge-transformed before comparative analyses.
Continuous data were compared using Student t tests.
Exploratory analyses were performed to identify any
potential factors inﬂuencing patients’ willingness to par-
ticipate. The information available on invited patients
was limited to their age, gender, ethnicity, general prac-
tice and last recorded eGFR. These ﬁve factors were
therefore assessed by binary logistic regression using a
forced enter method with regard to their impact on the
patient’s research participation. Patients who expressed
interest in participating were categorised as ‘willing invi-
tees’, whereas patients who either did not respond to
the invitation or replied but declined participation were
grouped together as ‘non-willing invitees’. Patients’
gender (male/female) and ethnicity (white/others)
were analysed as dichotomous data, whereas age and last
recorded eGFR were analysed as continuous data.
Supplementary analyses were performed with eGFR
being dichotomised either into CKD stage 3a (eGFR:
45–59 mL/min/1.73 m2) and stage 3b (eGFR: 30–
44 mL/min/1.73 m2) or into categories above or below
the median of eGFR (54 mL/min/1.73 m2).
Non-linearity of age and eGFR were examined using
restricted cubic spline models. Models were selected on
achieving a signiﬁcant improvement in Akaike’s
Information Criterion. Statistical signiﬁcance was
deﬁned as a two-tailed p value <0.05.
RESULTS
All 71 primary care practices within the former South
Birmingham Primary Care Trust with more than 3000
patients registered were invited to participate. Eleven
practices (15%) agreed to take part, with a total popula-
tion of 112 462 (table 1). Electronic database searches
identiﬁed 2044 potentially eligible patients. A further
446 (21.8%) patients were excluded by their GPs with
the proportion excluded varying considerably (2.3–
52.6%). Five of the 11 practices were known to be
‘research active’. There was no statistically signiﬁcant dif-
ference in regard to proportions of patients excluded
between ‘research-active’ practices compared to their
counterparts (median 19 (IQR 10–47) vs 11 (IQR 4–28)
%, p=0.2).
Invitation to study participation
The trial started in July 2013. A total of 1598 invitation
letters were sent out to all potentially eligible patients
(ﬁgure 1). Sixty-three per cent were women with a mean
age of 71 (SD 12) years, and a median eGFR of 53 (IQR
48–57) mL/min/1.73 m2. Most patients’ (84%) last
eGFR readings were within the range of 45–59 mL/
min/1.73 m2. The ethnicity was 83.4% white British,
3.4% black British, 3.3% South Asian, 1% mixed or
other ethnicity, and 8.9% unknown.
Patients’ response to study invitation letter
Responses were received from 733 patients (46%) who
had a mean age of 73 (SD 11) years. Of these, 196
(12%) expressed interest in participating in the study.
Percentages of those who were interested in participa-
tion ranged from 9% to 18% across the 11 practices
(table 1).
Of the 537 patients who responded declining partici-
pation, 295 (55%) did not wish to take a new medica-
tion, 220 (41%) did not wish to be part of a research
trial, 134 (25%) indicated that they did not have time to
take part in the study, 86 (16%) did not wish to have
further blood tests, 48 (9%) were unable to attend the
surgery, 21 (4%) believed kidney problems were of no
concern to them and 80 (15%) did not give a reason.
Other reasons for non-participation detailed in the free-
text area on the research reply slip included old age,
poor mobility, presence of other health issues, concerns
regarding the side effects of spironolactone, reluctance
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Table 1 Eleven recruiting practices’ population, prevalence of stage 3–5 CKD, numbers of patients invited, screened and randomised for STOP-CKD study
Practice
Practice
population
Prevalence of
stage 3–5 CKD*
(%)
Patients eligible
from computerised
search (%)
Patients
excluded by
GP (%)†
Patients
invited (%)
Patients
replying
(%)‡
Patients
expressing
interest (%)§
Patients
attending
screening visit
(%)§
Patients
randomised
(%)§
#1¶ 7501 4.72 260 (3.5) 49 (18.8) 211 (2.8) 105 (49.8) 37 (17.5) 22 (10.4) 3 (1.4)
#2¶ 3838 1.86 38 (1.0) 20(52.6) 18 (0.5) 7 (38.9) 3 (16.7) 3 (16.7) 0
#3 27 025 4.82 360 (1.3) 183 (50.8) 177 (0.6) 102 (57.6) 21 (11.9) 15 (8.5) 1 (0.6)
#4 7113 3.58 179 (2.5) 7 (3.9) 172 (2.4) 81 (47.1) 20 (11.6) 12 (7.0) 2 (1.2)
#5 24 553 2.97 478 (1.9) 97 (20.3) 381 (1.6) 152 (39.9) 41 (10.8) 29 (7.6) 5 (1.3)
#6 ¶ 8729 4.19 157 (1.8) 17 (10.8) 140 (1.6) 61 (43.6) 20 (14.3) 16 (11.4) 3 (2.1)
#7 ¶ 5817 4.69 129 (2.2) 13 (10.1) 116 (2.0) 44 (37.9) 15 (12.9) 10 (8.6) 1 (0.9)
#8 4824 3.58 114 (2.4) 13 (11.4) 101 (2.1) 44 (43.6) 11 (10.9) 10 (9.9) 0
#9 9436 6.67 236 (2.5) 25 (10.6) 211 (2.2) 97 (46.0) 19 (9.0) 12 (5.7) 0
#10 7104 2.75 43 (0.6) 1 (2.3) 42 (0.6) 27 (64.3) 6 (14.3) 3 (7.1) 1 (2.4)
#11 ¶ 6522 2.97 50 (0.8) 21 (42.0) 29 (0.4) 13 (44.8) 3 (10.3) 2 (6.9) 0
Total 112 462 2044 446 1598 733 196 134 16
Mean % 3.89 1.82 21.8 1.42
% Indicates percentage of total practice population.
*Data obtained from Quality and Outcomes Framework 2013/2014 report.
†Indicates percentage of potentially eligible patients excluded by their general practitioner.
§Indicates percentage of patients invited.
¶Signify general practices which were research-active and had dedicated on-site practice research nurses.
‡Percentage of patients who replied to the STOP-CKD research invitations.
CKD, chronic kidney disease; GP, general practitioner; STOP-CKD, Spironolactone To Prevent Cardiovascular Events in Early Stage CKD.
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to take additional medication, work commitments, being
carer for other family members, being away from home
during trial period, as well as unawareness of CKD
diagnosis.
In a logistic regression model, age, male gender and
coming from research-active practices were associated
with a greater willingness to participate in the trial,
whereas ethnicity and levels of eGFR were not predictive
(table 2). Age was noticeably non-linear in relation to
recruitment, with younger and older age associated with
a lower likelihood of agreeing to participate in the study
(ﬁgure 2).
Screening visit
Of the 196 patients who initially expressed an interest in
participating in the study, 134 patients (69%) actually
Figure 1 The CONSORT flow diagram of STOP-CKD study. *Some patients had multiple reasons for ineligibility. **Multiple
adverse reaction to antihypertensive in the past and previous endovascular aortic aneurysm repair which would affect pulse wave
velocity measurements. AE, adverse event; BP, blood pressure; eGFR, estimated glomerular filtration rate; STOP-CKD,
Spironolactone To Prevent Cardiovascular Events in Early Stage Chronic Kidney Disease.
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attended the screening visit. The characteristics of these
patients are presented in table 3. The cause of CKD was
unclear in the majority of the patients, and only 17
patients (13%) had a documented cause of CKD. The
median last-recorded MDRD eGFR was 55 (IQR 51–57)
mL/min/1.73 m2 with 88% within the range of 45–
59 mL/min/1.73 m2.
In total, 52 (39%) patients were found to be ineligible
for the study during the screening visit. The reasons for
exclusion are listed in ﬁgure 1. The main cause for
exclusion was low BP. Thirty-two patients had an ofﬁce
SBP lower than 120 mm Hg, with 16 patients receiving at
least one antihypertensive agent, although ﬁve of these
patients were known to have ischaemic heart disease,
and thus, another potential indication for treatment
with these agents other than hypertension. Of the 79
remaining eligible patients, a further 46 were excluded
after the screening blood test (ﬁgure 1). The main
reason for exclusion (31 patients) was having an eGFR
>60 mL/min/1.73 m2.
Randomisation visit
Of the 33 remaining eligible patients, 28 (85%)
attended the randomisation visit (ﬁgure 1). A further 12
patients were excluded at this point. Eight had an ofﬁce
SBP <120 mm Hg, three had postural hypotension, and
one had uncontrolled hypertension. Sixteen patients
were randomised, and their baseline characteristics are
shown in table 3.
Early termination of study
In May 2014, the STOP-CKD study was terminated early
because of futility. In order to achieve the original
planned sample size of 240 patients, the projected
number of primary care practices required to be
involved in the study would be 145 practices covering a
population of more than 1.5 million. After thorough dis-
cussion, the trial Data Monitoring and Ethics
Committee, and the Trial Steering Committee collect-
ively agreed that the study was not feasible with the allo-
cated resources.
DISCUSSION
In the UK, as indeed in many countries, most patients
with early-stage CKD are managed in primary care.
Many observational studies have established that these
patients have several differences compared with patients
managed in secondary care.32 They tend to be older
Figure 2 Relative odds and 95% CI of recruitment by age
using restricted cubic spline. Solid line indicates estimate and
dotted lines 95% CIs.
Table 2 Logistic regression demonstrating factors associated with increased likelihood of patients’ willingness to participate
in the trial (age as restricted cubic spline)
Variable OR Lower 95% CI Upper 95% CI p Value
Intercept 0.01931 0.00095 0.394 0.0103
eGFR 1.00513 0.98076 1.030 0.6827
Male gender 1.36905 1.00544 1.864 0.0461
White ethnicity 1.51474 0.96679 2.373 0.0699
Research active practice 1.42223 1.04079 1.943 0.0270
AGE 1.02677 0.97659 1.080 0.3014
AGE 1 0.93568 0.79398 1.103 0.4275
AGE 2 0.79572 0.15232 4.157 0.7865
AGE 3 3.30525 0.10044 108.771 0.5024
p for non-linearity for age 0.0111
p for overall effect of age 0.0003
Bold typeface highlights factors shown to have statistically significant association with increased likelihood of patients’ willingness to
participate in the trial (p<0.05).
eGFR, estimated glomerular filtration rate.
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with a lower prevalence of proteinuria and more pre-
served eGFR.32 These differences are important if any
intervention shown to be effective for the treatment of
CKD in the minority of patients treated in secondary
care is rolled out to the community. The STOP-CKD
trial was an attempt to establish whether low-dose
Table 3 Baseline demographics, clinical characteristics, blood pressure measurements and biochemistry profiles of patients
attended screening visit, and patients randomised to receive trial medication.
Attended screening visit
Randomised
into STOP-CKD study
Number of patients 134 16
Male gender, n. (%) 62 (46) 7 (44)
White ethnicity, n. (%) 125 (93) 16 (100)
Mean age (SD), years 68 (10) 71 (7)
Medical history, n (%)
Hypertension 62 (46) 5 (31)
Hypercholesterolaemia 42 (31) 3 (19)
Coronary heart disease 17 (13) 1 (6)
Coronary artery bypass graft/angioplasty 13 (10) 0
Stroke/transient ischaemic attack 11 (8) 1 (6)
Peripheral vascular disease 8 (6) 0
Total number of comorbidities, median (IQR) 1 (0–2) 0 (0–1)
Medications, n (%)
Antiplatelet agents 34 (25) 4 (25)
Lipid lowering agents 54 (40) 4 (25)
Use of antihypertensive agents 74 (55) 9 (56)
Diuretics 20 (15) 1 (6)
β-blockers 20 (15) 2 (13)
ACEi/ARB 48 (36) 5 (31)
Nitrates 5 (4) 0
Calcium channel blockers 21 (16) 4 (25)
α channel blockers 11 (8) 0
Patients not receiving any antihypertensive agents 60 (45) 7 (44)
Smoking history, n (%)
Current smoker 8 (6) 1 (6)
Ex-smoker 55 (41) 7 (44)
Never smoker 71 (53) 8 (50)
BP measurements
Office systolic BP, mean (SD), mm Hg 132 (19) 133 (10)
Office diastolic BP, mean (SD), mm Hg 79 (10) 78 (8)
Office systolic BP ≥140 or diastolic BP ≥90 mm Hg, n. (%) 47 (35) 10 (62)
Office BP within NICE CKD targets, n. (%) 54 (40) 6 (38)
Office systolic BP <120 mm Hg, n. (%) 34 (25) 0
Number of patients 79 16
Na+, mmol/L 141 (3) 142 (2)
K+, mmol/L 4.5 (0.6) 4.5 (0.4)
Urea, mg/dL 6.8 (2.0) 6.9 (1.4)
Creatinine, median (IQR), μmol/L 98 (85–112) 101 (86–121)
MDRD eGFR (median, IQR), mL/min/1.73 m2 57 (51–65) 54 (48–57)
CKD EPI eGFR (mean, SD), mL/min/1.73 m2 59 (12) 53 (7)
Urine ACR (median, IQR), mg/mmol 0.9 (0–2.0) 0.85 (0.08–1.95)
<3 mg/mmol, n. (%) 62 (79) 13 (81)
3–30 mg/mmol, n. (%) 16 (20) 3 (19)
>30 mg/mmol, n. (%) 1 (1) 0
Ca+2, mmol/L 2.38 (0.10) 2.38 (0.13)
Albumin, g/L 46 (2) 45 (1)
Total protein, g/L 72 (4) 71 (3)
Alkaline phosphatase, U/L 78 (25) 79 (17)
Alanine Aminotransferase, U/L 20 (8) 19 (7)
Bold typeface indicates categories of variables.
ACEi, ACE inhibitor; ACR, albumin:creatinine ratio; ARB, angiotensin II receptor blocker; BP, blood pressure; Ca+2, serum calcium; CKD,
chronic kidney disease; EPI, Epidemiology Collaboration equation; eGFR, estimated glomerular filtration rate;; K+, serum potassium; MDRD,
modification of diet in renal disease; Na+, serum sodium; NICE, National Institute for Health and Care Excellence; STOP-CKD,
Spironolactone To Prevent Cardiovascular Events in Early Stage CKD.
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spironolactone, a treatment shown to be safe and effect-
ive in improving surrogate markers of CV risk in patients
with CKD managed in secondary care, was equally safe
and effective in patients with CKD managed in primary
care. Although the study proved not to be feasible, there
are several important ﬁndings and lessons that can be
learnt from it to inform future interventional studies in
this population.
Estimating the number of patients needed
Assessing the number of patients needed to invite in
order to recruit to the sample size is an essential but
challenging requirement in planning any study.
Recently, a Japanese study explored the use of informa-
tion technology in predicting the success or failure of
study recruitment.33 The study derived the eligible EPR
index by dividing the number of eligible patients identi-
ﬁed from the EPR by the target sample size. An EPR
index of more than 1.7 was reported to have a sensitivity
and speciﬁcity of approximately 70% and 100%, respect-
ively, in predicting recruitment success. However, in
spite of a much higher EPR index of 6.7 that should
have predicted successful recruitment, the STOP-CKD
study failed to reach its target sample size, suggesting
that other recruitment issues were involved.
Following the EPR search, the number of patients eli-
gible for invitation reduced considerably after GP review.
The variation observed in the proportion of patients
excluded by GPs across the practices suggests that there
were large elements of subjectivity and inconsistency in
this assessment. It is likely that many patients fulﬁlling
the inclusion criteria were excluded at this stage. While
the review of the list of potential participants by their
corresponding GPs was well intentioned, signiﬁcant
selection-bias might have occurred during the process,
and we suggest that in future studies, this step requires
revision with clear and transparent criteria.
Prevalence of CKD
In the UK, primary care physicians are required to keep
a register of patients with stages 3–5 CKD.34 35 Published
data from the participating practices showed the average
percentage of total patients on the CKD register was
3.89%, which is lower than the recently published
reports from UK research databases of 5.15%34 and
5.9%,36 and marginally lower than that reported for all
English practices over 2010–2012 of 4.3%.37
Nevertheless, it appears that the observed prevalence of
CKD is much lower than the 10% ﬁgure which was the
ﬁnding in previous epidemiological work in the UK38
and globally.6 39 It has been suggested that the preva-
lence of CKD has been signiﬁcantly overestimated by
using a single serum creatinine measurement to deﬁne
CKD,40 and this has been conﬁrmed in a recent UK
study using two creatinine measurements which
reported a CKD prevalence of 3.9%.34
In order to increase patient inclusivity and bypass the
issues of uncoded or miscoded CKD,34 we searched and
shortlisted all patients with a latest recorded eGFR of
30–59 mL/min/1.73 m2 in the preceding 12 months.
The eGFR test performed at the screening visit served as
a conﬁrmation of CKD diagnosis. Despite having an
eGFR within 30–59 mL/min/1.73 m2 previously, 40% of
such patients were excluded due to an eGFR >60 mL/
min/1.73 m2 at screening, and therefore, by deﬁnition
did not have CKD stage 3. Of those who fulﬁlled the bio-
chemical eligibility criteria, most had only a modest
reduction in eGFR, with a median eGFR of 54 mL/min/
1.73 m2, and none were found to have signiﬁcant levels
of albuminuria.
Blood pressure
The treatment of hypertension is still the cornerstone of
management of CKD, both in terms of CKD progression
and the reduction of CV risk.41 42 In agreement with
other studies, we found less than half the patients
attending the screening visit achieved both the SBP and
DBP target recommended by NICE CKD guidelines.32 38
Among those with SBP ≥140 mm Hg or DBP
≥90 mm Hg, more than 40% were, in fact, not receiving
any antihypertensive medication.
It has long been believed that lowering ofﬁce/clinic
BP to levels lower than 120/80 mm Hg is associated with
worse outcomes and increased mortality, especially in
the elderly.43 This is reﬂected in recent guidelines on
the management of CKD that recommend BP not be
lowered below these levels.25 44 The results of the recent
SPRINT trial challenge these guidelines,45 and future
studies might consider the inclusion of such patients.
Widening inclusion criteria
Faced with persistent recruitment difﬁculties, consider-
ation to widen the STOP-CKD study eligibility criteria
had been suggested. However, the eligibility criteria
remained unchanged as each was believed to be essen-
tial not only in safeguarding patients’ safety, but also
ensuring validity of the research study.
Patients with diabetes represent a signiﬁcant subgroup
of the CKD population. It is possible that as such
patients have more regular contact with the healthcare
professionals; they might potentially be more aware of
their disease label and more willing to participate in the
study. However, as patients with diabetes are known to
have higher risk of hyperkalaemia and the pathophysi-
ology of their increased arterial stiffness is likely to be
different to those without, the inclusion of this subgroup
of patients in this pilot study would result in a small
study population too heterogeneous to effectively
address the primary research question. Although the
STOP-CKD study was unable to include patients with
diabetes, the challenges faced by the study, and lessons
learnt from it, have thus far been used to inform the
ongoing Beneﬁts of Aldosterone Receptor Antagonism
in Chronic Kidney Disease (BARACK D) study,46 a large
prospective, randomised, open blinded end point trial
aiming to determine the effect of low-dose
8 Ng KP, et al. BMJ Open 2016;6:e010519. doi:10.1136/bmjopen-2015-010519
Open Access
group.bmj.com on April 28, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
spironolactone on mortality and CV outcomes in
patients with stage 3b CKD in primary care.
Encompassing stage 3b CKD population with a minimal
SBP of 100 mm Hg, and including those with type 2 DM;
the participants’ criteria of BARACK D study, therefore,
varies somewhat from that of the STOP-CKD. Its ﬁnd-
ings, assuming the trial successfully recruits, are there-
fore eagerly anticipated.
Primary care practice recruitment strategies
Though we designed the STOP-CKD study to minimise
any extra workload on the participating primary care
practices, most practices declined the initial approach,
and it took a lot of effort from the investigators to
recruit the 11 practices that participated. In order to
improve the quality and increase the quantity of primary
care research in the UK, a ‘research-ready self-
accreditation’ initiative to support general practices in
meeting the legal requirements of the UK for carrying
out research.47 Thus far, there are more than 1000
research-ready general practices in the UK.48 Our study
demonstrated a signiﬁcant positive inﬂuence of
research-active practices on patients’ participation pro-
viding further support for these measures.
In addition, an integrated system which allows research-
ers to run complex searches over anonymised population-
level health records, such as FARSITE, has proven to be a
rapid method in testing research feasibility, providing
accurate selection of a large patient population from a
greater number of GP practices, facilitating administrative
processes and, importantly, minimising research work-
load for the practices.49 Innovative set-up of a more cohe-
sive health informatics system looks to be the key in sup-
porting and delivering faster and more effective research
evidence of the real world for the future.50
Patient recruitment strategies
Although the need for a robust evidence base for any
intervention before it becomes accepted practice is now
well established, there is surprisingly little evidence on
how best to conduct an RCT.51 52 Regulatory and ethical
issues compelled us to contact potentially eligible
patients by mailshot through their GPs. This is a notori-
ously inefﬁcient and costly process with a large number
of invitations needing to be sent to recruit the target
number of patients. Two key reviews previously explored
the value of various strategies in improving participants’
recruitment in research studies.51 53 The STEPS study
suggested that being ﬂexible and robust in adapting to
unexpected issues was important to ensure trials
success,53 while in the systematic review by Treweek
et al,51 telephone reminders to non-responders, opt-out
rather than opt-in system of being contacted about the
study, ﬁnancial incentives and open designs all appeared
to be effective strategies.
We suggest that an initial approach using telephone,
text or email may yield better results, and that further
research examining the acceptability and efﬁcacy of
initial recruitment strategies is of major importance. In
addition, the effects of shortening patients’ information
sheet,54 using computer pop-ups on patients’ electronic
health records to highlight potential participants, mini-
mising frequency of research visits and optimising the
use of healthcare informatics for research data collec-
tion also worth exploring. Importantly, it is plausible
that the issue of low awareness of CKD diagnosis among
the patients55 might have negatively impacted on the
recruitment of the STOP-CKD study. Efforts in develop-
ing wider recruitment strategies which focus on increas-
ing potential participants’ awareness and understanding
of CKD should therefore be considered.56 Suggested
methods to improve CKD research recruitment in
primary care are listed in box 2.
Our logistic regression model showed that younger
and older patients were signiﬁcantly less likely to partici-
pate. Thus, although we designed the study with broad
inclusivity criteria, we still did not manage to recruit the
‘real-life CKD population’ which may reﬂect patients’
self-selection bias. Strategies to recruit these patients
therefore need developing and testing in future studies.
CONCLUSIONS
The STOP-CKD study was a non-age-restricted,
investigator-led, feasibility RCT designed to inform a
future larger, hard end point study in patients with CKD
in primary care. The study highlighted the unique
characteristics of the CKD population in primary care,
which challenged our preconceived knowledge about
the appropriate intervention and management of this
sizeable group of patients. With the majority of interven-
tional studies on patients with CKD thus far based in sec-
ondary care, there remains an urgent need to optimise
the generalisability of future CKD research, especially in
primary care. The experience and lessons learnt from
this study provide important information for all CKD
researchers to meticulously reﬂect on their future
research aims, study design, choices of intervention, and
most importantly, recruitment strategies. As Henry Ford
once said, ‘failure is only the opportunity to begin
again, only this time more wisely’.
Box 2 Suggested methods to improve chronic kidney
disease (CKD) research recruitment in primary care
▸ Open design
▸ Concise patient information sheet
▸ Minimise frequency of research visit
▸ Optimise use of routinely collected data via healthcare
informatics
▸ Telephone, text or email as initial approach and reminder for
non-responder
▸ Financial incentives/eliminating financial disincentives
▸ Computer pop-ups on healthcare records
▸ Increase disclosure of CKD diagnosis from healthcare provi-
ders to patients
▸ Improve patients’ understanding of CKD and its implications.
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